New medication coming to Memphis to help stroke victims

Memphis, Tenn. — Relief could be on the way for Mid-South residents who have suffered one of the most damaging types of strokes.

The University of Tennessee’s Health Science Center’s Stroke Team is joining over 100 hospitals worldwide to participate in a research study called FASTEST (rFV11a for Acute Hemorrhagic Stroke Administered at Earliest Time).

The study will test the safety and efficacy of V11a to prevent hemorrhage expansion in patients with strokes caused by bleeding in the brain, also known as intracerabral hemorrhage strokes.

Intracerebal hemorrhage produces the most devastating of all strokes, with more than 40 percent of patients dying within the first 30 days and only 20 percent of patients able to return to an independent life after six months, according to a release from The University of Tennessee Health Science Center.

The UTHSC Stroke Team said almost 300 people in the Mid-South suffer from this type of stroke a year.

There’s currently no treatment for this condition that is able to improve outcomes or stop the bleeding expansion.

Researchers, however, are hopeful that V11a, a protein made in the human body to stop bleeding at the site of injury to a blood vessel, is the answer.

Methodist University Hospital and the UTHSC Mobile Stroke Unit are both taking part in the study.